Developing IL-2 Variant Immunocytokines for Immunotherapy of Cancer

Time: 9:25 am
day: Day One

Details:

  • Design and preclinical properties of IL-2 variant immunocytokines
  • Tumor versus PD-1 targeting
  • Application for combination therapy

Speakers: